Evaluating the quality of life associated with rifabutin prophylaxis for Mycobacterium avium complex in persons with AIDS: combining Q-TWiST and multiattribute utility techniques

D. A. Revicki, K. N. Simpson, Albert W Wu, R. L. LaVallee

Research output: Contribution to journalArticle

Abstract

Our objective was to evaluate the effect of rifabutin prophylaxis in patients with AIDS and CD4 counts of less than 200 per cubic millimetre using a combination of Q-TWIST (quality-adjusted time without symptoms and toxicity) and multiattribute health utility assessment. The design consisted of a secondary analysis of two previously reported multicentre, randomized, placebo-controlled clinical trials conducted in 78 academic, community and Department of Veterans Affairs HIV centres and private practices. 542 patients with AIDS and CD4 counts of less than 200 per cubic millimetre were assigned to rifabutin 300 mg/day and 562 were assigned to a placebo. A modified Q-TWiST approach was used for comparing treatments based on the occurrence and duration of time with and without severe symptoms and clinical endpoints. Health states were constructed to represent combinations of clinical events experienced by study patients. Five physicians assigned utilities for health states using a six-attribute health classification system. These utilities were used to adjust survivial for QOL. The rifabutin and placebo groups were compared using estimated quality-of-life-adjusted days. The incidence of MAC was 9% for the rifabutin group and 18% for the placebo group (p

Original languageEnglish (US)
Pages (from-to)309-318
Number of pages10
JournalQuality of Life Research
Volume4
Issue number4
DOIs
StatePublished - Aug 1995

Fingerprint

Rifabutin
Mycobacterium avium Complex
Acquired Immunodeficiency Syndrome
Placebos
Quality of Life
Health
CD4 Lymphocyte Count
Private Practice
Veterans
Randomized Controlled Trials
HIV
Physicians
Incidence

Keywords

  • Acquired immunodeficiency syndrome
  • multiattribute utility measurement
  • Q-TWiST analysis
  • quality of life assessment
  • rifabutin prophylaxis

ASJC Scopus subject areas

  • Nursing(all)
  • Rehabilitation

Cite this

@article{786a2e20fe3e47fa96878fe48a437c07,
title = "Evaluating the quality of life associated with rifabutin prophylaxis for Mycobacterium avium complex in persons with AIDS: combining Q-TWiST and multiattribute utility techniques",
abstract = "Our objective was to evaluate the effect of rifabutin prophylaxis in patients with AIDS and CD4 counts of less than 200 per cubic millimetre using a combination of Q-TWIST (quality-adjusted time without symptoms and toxicity) and multiattribute health utility assessment. The design consisted of a secondary analysis of two previously reported multicentre, randomized, placebo-controlled clinical trials conducted in 78 academic, community and Department of Veterans Affairs HIV centres and private practices. 542 patients with AIDS and CD4 counts of less than 200 per cubic millimetre were assigned to rifabutin 300 mg/day and 562 were assigned to a placebo. A modified Q-TWiST approach was used for comparing treatments based on the occurrence and duration of time with and without severe symptoms and clinical endpoints. Health states were constructed to represent combinations of clinical events experienced by study patients. Five physicians assigned utilities for health states using a six-attribute health classification system. These utilities were used to adjust survivial for QOL. The rifabutin and placebo groups were compared using estimated quality-of-life-adjusted days. The incidence of MAC was 9{\%} for the rifabutin group and 18{\%} for the placebo group (p",
keywords = "Acquired immunodeficiency syndrome, multiattribute utility measurement, Q-TWiST analysis, quality of life assessment, rifabutin prophylaxis",
author = "Revicki, {D. A.} and Simpson, {K. N.} and Wu, {Albert W} and LaVallee, {R. L.}",
year = "1995",
month = "8",
doi = "10.1007/BF01593883",
language = "English (US)",
volume = "4",
pages = "309--318",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Evaluating the quality of life associated with rifabutin prophylaxis for Mycobacterium avium complex in persons with AIDS

T2 - combining Q-TWiST and multiattribute utility techniques

AU - Revicki, D. A.

AU - Simpson, K. N.

AU - Wu, Albert W

AU - LaVallee, R. L.

PY - 1995/8

Y1 - 1995/8

N2 - Our objective was to evaluate the effect of rifabutin prophylaxis in patients with AIDS and CD4 counts of less than 200 per cubic millimetre using a combination of Q-TWIST (quality-adjusted time without symptoms and toxicity) and multiattribute health utility assessment. The design consisted of a secondary analysis of two previously reported multicentre, randomized, placebo-controlled clinical trials conducted in 78 academic, community and Department of Veterans Affairs HIV centres and private practices. 542 patients with AIDS and CD4 counts of less than 200 per cubic millimetre were assigned to rifabutin 300 mg/day and 562 were assigned to a placebo. A modified Q-TWiST approach was used for comparing treatments based on the occurrence and duration of time with and without severe symptoms and clinical endpoints. Health states were constructed to represent combinations of clinical events experienced by study patients. Five physicians assigned utilities for health states using a six-attribute health classification system. These utilities were used to adjust survivial for QOL. The rifabutin and placebo groups were compared using estimated quality-of-life-adjusted days. The incidence of MAC was 9% for the rifabutin group and 18% for the placebo group (p

AB - Our objective was to evaluate the effect of rifabutin prophylaxis in patients with AIDS and CD4 counts of less than 200 per cubic millimetre using a combination of Q-TWIST (quality-adjusted time without symptoms and toxicity) and multiattribute health utility assessment. The design consisted of a secondary analysis of two previously reported multicentre, randomized, placebo-controlled clinical trials conducted in 78 academic, community and Department of Veterans Affairs HIV centres and private practices. 542 patients with AIDS and CD4 counts of less than 200 per cubic millimetre were assigned to rifabutin 300 mg/day and 562 were assigned to a placebo. A modified Q-TWiST approach was used for comparing treatments based on the occurrence and duration of time with and without severe symptoms and clinical endpoints. Health states were constructed to represent combinations of clinical events experienced by study patients. Five physicians assigned utilities for health states using a six-attribute health classification system. These utilities were used to adjust survivial for QOL. The rifabutin and placebo groups were compared using estimated quality-of-life-adjusted days. The incidence of MAC was 9% for the rifabutin group and 18% for the placebo group (p

KW - Acquired immunodeficiency syndrome

KW - multiattribute utility measurement

KW - Q-TWiST analysis

KW - quality of life assessment

KW - rifabutin prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=0029028794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029028794&partnerID=8YFLogxK

U2 - 10.1007/BF01593883

DO - 10.1007/BF01593883

M3 - Article

C2 - 7550179

AN - SCOPUS:0029028794

VL - 4

SP - 309

EP - 318

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 4

ER -